Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Figure 4

Kaplan-Meier curves of postadmission time until severe clinical progression in patients with severe COVID-19 patients with CRP/Alb ratios at admission. A log-rank test was used to evaluate differences between groups. The disease progression rates were 35.5% (50 of 141) and 1.9% (6 of 324) for the high CRP/Alb ratio(≥1.843) group and low CRP/Alb ratio (<1.843) group, respectively, at the observed endpoint (progression to critical COVID-19 cases), respectively ().